Susquehanna International Group, LLP Spring Works Therapeutics, Inc. Call Options Transaction History

Susquehanna International Group, LLP

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$32.04 - $42.76 $611,964 - $816,716	19,100 Added 335.09%	24,800 $794,000
Q2 2024 Aug 15, 2024	SELL	$36.06 - $47.62 $6.33 Million - $8.36 Million	-175,500 Reduced 96.85%	5,700 $214,000
Q1 2024 May 07, 2024	BUY	$36.5 - $52.5 $3.26 Million - $4.69 Million	89,300 Added 97.17%	181,200 $8.92 Million
Q4 2023 Feb 14, 2024	BUY	$18.94 - $37.24 $1.74 Million - $3.42 Million	91,900 New	91,900 $3.35 Million
Q1 2023 May 16, 2023	SELL	$24.97 - $34.05 $1.05 Million - $1.44 Million	-42,200 Reduced 31.68%	91,000 $2.34 Million
Q4 2022 Feb 14, 2023	BUY	$21.73 - $28.72 $554,115 - $732,360	25,500 Added 23.68%	133,200 $3.46 Million
Q3 2022 Nov 14, 2022	BUY	$24.1 - $39.66 $2.31 Million - $3.8 Million	95,900 Added 812.71%	107,700 $3.07 Million
Q2 2022 Aug 15, 2022	SELL	$18.36 - $60.07 $3.33 Million - $10.9 Million	-181,600 Reduced 93.9%	11,800 $291,000
Q1 2022 May 16, 2022	BUY	$48.97 - $65.46 $9.47 Million - $12.7 Million	193,400 New	193,400 $10.9 Million

238

69.8M

144K

257K

Ticker SWTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,401,100
Market Cap $2.34B
Description
SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also deve...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.